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lowed by ASCT.
Patients undergoing CAR T-cell therapy are prone to CRS
which can be fatal. C-reactive protein (CRP) has been iden-
tiﬁed as a surrogate marker for CRS.
Intervention: Patients with aggressive rel/ref DLBCL receive
BEAM conditioning followed by ASCTon day 0 and CAR T-cell
infusion on days +2 and +3 per institutional protocol 12-117.
CRP levels are monitored daily for trends, and close surveil-
lance for signs/symptoms of CRS is performed. An algorithm
to guide management of CRS is included in all our CAR T-cell
therapy protocols (Fig. 1).
Findings: To date, six patients have been treated on this
protocol. Two of the six patients had CRS and were treated
according to the management guideline, and both patients
had a peak CRP >20 (Fig. 2). All patients had neutrophil
engraftment at the expected time point and remain in
remission at a median follow-up of 6 months.
Discussion & Implications: Preliminary ﬁndings based on
limited data show encouraging results for use of CAR T-
cell therapy in this patient population. A correlation wasTable 1
Comparison of Pre and Post Intervention Times
Pre
Time To: n Median IQR
Vitals 24 4 2-11
Blood Culture 22 38 30-60
Antibiotics 20 114 93-168
Transfer to Unit 24 211 181-257
Figure 1. BPA to alert clinicians to BMT history and the need for immediate assessmen
Epic Systems Corporation. Used with permission.seen in incidence of CRS when CRP was >20. This has been
seen in previous studies and may help to better identify
patients at risk for developing CRS. The CRS management
algorithm serves as a guideline: the immunomodulatory
agents (speciﬁcally dexamethasone) included in the al-
gorithm run the risk of muting the action of the CAR T-
cells. Thus, the risk of implementing this algorithm needs
to be weighed against the risk of progression of lymphoid
malignancy. In this protocol, a lower threshold for acti-
vating the management algorithm is utilized as the risk of
death from CRS exceeds that of death due to primary
disease. This trial is ongoing, and updated results are
forthcoming.BMT ADMINISTRATORS/QUALITY
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Background: Rapid evaluation and antibiotic therapy for
febrile bone marrow transplant (BMT) patients is critical
to decrease morbidity and mortality from infection, but
identifying these patients in a large medical system can be
challenging. This study measures the effect of computer-
ized triage support implemented in an EmergencyPost p-value
n Median IQR
39 5 3-9 0.32
33 41 25-66 0.45
34 79 61-135 <0.01
39 174 152-320 0.28
t. The BPA also sends pages to ED LIPs, charge nurse and the BMT team.  2014
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to antibiotic administration and other time-sensitive
measures. We hypothesize that triage support will
decrease time to vitals, blood cultures, antibiotics, and
unit transfer.
Methods: A before-after interventional study was conducted
of all adult (age  18) patients with history of BMT and fever
>37.1C admitted from a 60,000-visit university ED with an
active BMT program between October 2011 and July 2014.
Cohorts were deﬁned by implementation of a computerized
triage support advisory in February 2013. This system was
comprised of a best practice advisory (BPA) using both a
computer prompt and an automated page to alert clinicians
to the history of recent BMT. The primary outcome was time
to antibiotics, and secondary outcomes included time to vital
signs, blood cultures, and transfer. A one-sided Wilcoxon
rank-sum test was used to compare before-after intervention
times, and the Chi-squared test was used for comparisons of
proportions. Statistical tests were assessed for signiﬁcance at
the 5% level.
Results: Sixty-three patients were included in the study, and
most had blood cultures drawn and antibiotics started
empirically (87% and 86%, respectively). Median time to an-
tibiotics was lower after BPA implementation (79 vs. 114 min,
p<0.01). Despite earlier antibiotic administration, the rate of
blood cultures (85% after vs. 92% before, p¼0.67) and anti-
biotics (87% vs. 83%, p¼0.96) did not change. No differences
were observed in time to vital signs, blood culture, or ED
disposition did not change.
Conclusion: Computerized triage support was associated
with decreased time to antibiotics, without increased health
care utilization. Further studies designed to better under-
stand the role of enhanced triage tools and EMR screening
protocols are critical to standardizing care and identifying
patients at high risk of clinical deterioration.519
Meeting Retrospective: Deﬁning Quality and Value in
Stem Cell Transplant 2014 Forum
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In July 2014, the National Marrow Donor Program/Be The
Match’s (NMDP) Advisory Group on Financial Barriers to
Transplant convened a working forum in Minneapolis,
MN attended by over 100 stem cell transplant (SCT)
community representatives. Forum participants included
transplant center medical and program directors, national
payers and reinsurers and leadership from the Founda-
tion for the Accreditation of Cellular Therapy (FACT), the
American Society of Blood and Marrow Transplant
(ASBMT) and the Center for International Blood and
Marrow Transplant (CIBMTR). Speakers at the forum
discussed their perspectives on how the SCT ﬁeld can
develop approaches to measure quality and improve
value for patients. At the conclusion of the forum many
recommendations for the SCT community emerged
through several roundtable and full group discussions. (1)
The SCT community needs to develop a stronger rela-
tionship with referring physicians to ensure timely pa-
tient referral to transplant which is associated with better
outcomes. Early referral could serve as a quality metric
for the hematologic community tied to the patient’soverall care experience. Payer engagement in referral
timing is an underutilized potential resource. (2) Leverage
data available to transplant centers from the CIBMTR’s
Stem Cell Transplant Outcomes Database (SCTOD) to
identify utilization patterns that need further study. (3)
SCT community leadership and organizations should
develop a venue for ongoing dissemination and discus-
sion of promising care in SCT that take into account FACT
ﬁndings, SCTOD analysis and ASBMT guidelines for overall
quality improvement. (4) Develop draft SCT quality
measures and test them among transplant centers. (5)
Identify components of quality measurement in SCT that
would be appropriate for use in quality or outcome based
reimbursement models. (6) Engage other communities in
the quality measure development process including the
physician societies like the American Society of Hema-
tology and the American Society of Clinical Oncology, the
National Quality Forum as well as employers, patients,
pharmaceutical manufactures and hospital level admin-
istrators and Chief Financial Ofﬁcers. Forum participants
found the meeting to be very engaging and useful for
their daily work in the SCT ﬁeld. A follow-up meeting is
scheduled for July 2015 in Minneapolis, MN where com-
munity speakers will present updates on quality measure
development.520
Experiences with Design and Implementation of a
Related Donor Coordinator Position
Lizeth Garcia-Jennings. Blood & Marrow Transplant Program,
University of Iowa Hospitals & Clinics, Iowa City, IA
Purpose: At our center, related donors were cared for by our
Patient Coordinators. In 2012, we decided to create a new
position, a Donor Coordinator position, which was modeled
after the NMDP workup specialist position. Our goal was to
provide related donors with the same education, care, and
emotional support that unrelated donors receive through the
National MarrowDonor Program (NMDP).We alsowanted to
improve the overall donor experience and service that the
donors receive. Also, due to FACT standards, we found it
necessary to create separate care teams for the donors and
recipients, while also being able to offer a donor advocate to
all donors.
Scope: We evaluated a related donor’s journey from initial
testing to follow-up. Key issues found were education prior
to testing, donor safety based on past medical history, and
administration of ﬁlgrastim.
Method: The Donor Coordinator position is in charge of the
donor’s care and conﬁrms separate teams for the donor and
recipient, while also serving as an advocate.
Education prior to initiation of testing was a main goal. A
health history questionnaire and educational documents
were created for the initial screening, testing, and education
of donors. Donors are educated of the whole process by
phone prior to testing and are screened by the Donor
Coordinator. Screening of donors is performed with a
standard health history questionnaire. Any medical condi-
tions that are present are reviewed by the Donor Coordi-
nator who consults the NMDP’s Medical Assessment at HR/
CT/WU. If the NMDP assessment suggests a deferral, then
the Donor Coordinator will send this information to our
Transplant Physician to make the ﬁnal decision on whether
to proceed with testing. If there are no concerns regarding a
